| scholarly article | Q13442814 |
| P50 | author | Gerald T Nepom | Q38546281 |
| P2093 | author name string | Jane H Buckner | |
| P2860 | cites work | Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity | Q24599806 |
| Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes | Q24632382 | ||
| Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5 | Q24635387 | ||
| Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases | Q24676659 | ||
| The role of PTPN22 risk variant in the development of autoimmunity: finding common ground between mouse and human | Q28081321 | ||
| Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease | Q28201947 | ||
| Glutamic acid decarboxylase and other autoantigens in IDDM | Q28283193 | ||
| Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation | Q29614840 | ||
| Proinsulin-Specific, HLA-DQ8, and HLA-DQ8-Transdimer–Restricted CD4+T Cells Infiltrate Islets in Type 1 Diabetes | Q57221938 | ||
| Cutting Edge: Increased IL-17-Secreting T Cells in Children with New-Onset Type 1 Diabetes | Q58328293 | ||
| Increased Numbers ofin vivoActivated T cells in Patients with Recent Onset Insulin-dependent Diabetes Mellitus | Q61863560 | ||
| Co-expression of CD45RA (naive) and CD45RO (memory) T-cell markers | Q62068073 | ||
| IL-21 Counteracts the Regulatory T Cell-Mediated Suppression of Human CD4+ T Lymphocytes | Q63325580 | ||
| Posttranslational Modification of HLA-DQ Binding Islet Autoantigens in Type 1 Diabetes | Q64166631 | ||
| Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development | Q79125427 | ||
| Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes | Q81464244 | ||
| Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes | Q82746957 | ||
| Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases | Q30419941 | ||
| The autoimmune-predisposing variant of lymphoid tyrosine phosphatase favors T helper 1 responses. | Q33570917 | ||
| Recurrence of autoimmunity following pancreas transplantation | Q33599426 | ||
| Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects | Q33604570 | ||
| Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. | Q33750748 | ||
| Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice. | Q33854444 | ||
| IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells | Q33990291 | ||
| Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline | Q34227866 | ||
| New insight on human type 1 diabetes biology: nPOD and nPOD-transplantation. | Q34240416 | ||
| Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes | Q34384116 | ||
| Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes | Q34393377 | ||
| A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes | Q34421851 | ||
| Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes | Q34428346 | ||
| Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. | Q34496667 | ||
| ZnT8-Specific CD4+ T cells display distinct cytokine expression profiles between type 1 diabetes patients and healthy adults | Q34580119 | ||
| An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells | Q34682216 | ||
| Th1/Th17 plasticity is a marker of advanced β cell autoimmunity and impaired glucose tolerance in humans | Q34756902 | ||
| Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes | Q34987849 | ||
| Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis | Q35025511 | ||
| Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes | Q35053311 | ||
| Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression | Q35097484 | ||
| Conversations with GAD. | Q35130068 | ||
| IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients | Q35153018 | ||
| Follicular helper T cell signature in type 1 diabetes | Q35242659 | ||
| Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects | Q35378628 | ||
| Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes | Q35405076 | ||
| Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development | Q35431818 | ||
| Antigen targets of type 1 diabetes autoimmunity | Q35852999 | ||
| Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. | Q36216535 | ||
| Allograft rejection mediated by memory T cells is resistant to regulation | Q36288969 | ||
| Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial | Q36292592 | ||
| The insulin A-chain epitope recognized by human T cells is posttranslationally modified | Q36403698 | ||
| Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia | Q36403785 | ||
| A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models | Q36802757 | ||
| Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes | Q36940282 | ||
| Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells | Q36968542 | ||
| The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors | Q37018786 | ||
| PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. | Q37396708 | ||
| Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells | Q37405753 | ||
| Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial | Q37642554 | ||
| Chromogranin A is a T cell antigen in human type 1 diabetes | Q37716863 | ||
| Th17 cells in type 1 diabetes | Q38068028 | ||
| Anti-CD3 clinical trials in type 1 diabetes mellitus | Q38111027 | ||
| Islet inflammation in human type 1 diabetes mellitus | Q38287783 | ||
| Advances in IL-21 biology - enhancing our understanding of human disease | Q38388319 | ||
| CD4 T cell differentiation in type 1 diabetes. | Q38535279 | ||
| Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions | Q38673368 | ||
| CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring. | Q39228782 | ||
| Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes. | Q39499765 | ||
| Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin | Q39796792 | ||
| Islet cell autoantigens in insulin-dependent diabetes | Q40305187 | ||
| Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus | Q40581531 | ||
| The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells | Q41146074 | ||
| Reactivated CD4+Tm cells of T1D patients and siblings display an exaggerated effector phenotype with heightened sensitivity to activation-induced cell death | Q41568883 | ||
| Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. | Q42224371 | ||
| IL-17 immunity in human type 1 diabetes | Q42997713 | ||
| Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes | Q43902397 | ||
| Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. | Q44051470 | ||
| Differential recognition and activation thresholds in human autoreactive GAD-specific T-cells | Q44901439 | ||
| GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes | Q44903844 | ||
| Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects | Q44914587 | ||
| Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes | Q44932416 | ||
| In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling | Q44982658 | ||
| Accumulation of autoreactive effector T cells and allo-specific regulatory T cells in the pancreas allograft of a type 1 diabetic recipient. | Q45860094 | ||
| Impaired CD4 and CD8 T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children | Q46202971 | ||
| Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus | Q46521582 | ||
| IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway | Q47765560 | ||
| Increased Th22 cells are independently associated with Th17 cells in type 1 diabetes. | Q47824146 | ||
| Th9 and Th22 immune response in young patients with type 1 diabetes | Q48090733 | ||
| High diversity in the TCR repertoire of GAD65 autoantigen-specific human CD4+ T cells. | Q50751841 | ||
| Autoantigen-specific memory CD4+ T cells are prevalent early in progression to Type 1 diabetes. | Q50971564 | ||
| Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. | Q51778586 | ||
| Variation in the CTLA4 3'UTR has phenotypic consequences for autoreactive T cells and associates with genetic risk for type 1 diabetes. | Q53650488 | ||
| Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. | Q53859655 | ||
| Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. | Q54537170 | ||
| Emergence of a Broad Repertoire of GAD65-Specific T-Cells in Type 1 Diabetes Patients with Graft Dysfunction after Allogeneic Islet Transplantation | Q57158416 | ||
| GAD65- and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects | Q57158887 | ||
| P921 | main subject | type-1 diabetes | Q124407 |
| P304 | page(s) | 44-50 | |
| P577 | publication date | 2016-03-03 | |
| P1433 | published in | Journal of Autoimmunity | Q15716783 |
| P1476 | title | Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes | |
| P478 | volume | 71 |
| Q59754899 | A multi-epitope DNA vaccine enables a broad engagement of diabetogenic T cells for tolerance in Type 1 diabetes |
| Q39280739 | Academic, Foundation, and Industry Collaboration in Finding New Therapies |
| Q45929111 | Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes. |
| Q90776706 | Beta cell-specific CD8+ T cells maintain stem cell memory-associated epigenetic programs during type 1 diabetes |
| Q39017669 | Beyond Genetics: What Causes Type 1 Diabetes |
| Q48617204 | Dominant TNFα and impaired IL-2 cytokine profiles of CD4+ T cells from children with type-1 diabetes. |
| Q90113269 | Reversal of Hyperglycemia and Suppression of Type 1 Diabetes in the NOD Mouse with Apoptotic DNA Immunotherapy™ (ADi™), ADi-100 |
| Q50158327 | The molecular basis of immune regulation in autoimmunity |
| Q91768573 | Treg cell-based therapies: challenges and perspectives |
Search more.